hey even more news on the news wire.....
Tuesday July 7, 8:15 am Eastern Time
Company Press Release
Wound Care Maturing Into the Fastest-Growing
Biotechnology Sector, Analyst Says
LOS ANGELES--(BW HealthWire)--July 7, 1998--Wound care has become ''a major target of
biotechnology companies,'' according to an analyst covering this sector.
The entire wound care biotechnology sector has been broken down, described and rated in a newly
released research report.
Alexander K. Arrow, vice president, research at Wedbush Morgan Securities in Los Angeles, has
issued a report describing companies competing in each of 11 different sub-sectors of the wound
care market.
The markets include the diabetic foot ulcer market, the severe burn market, the emergency room
wound-closing glue market and eight others. According to the report, each one is serving as a
battleground for companies developing competing wound care products
From the rivalry between Organogenesis Inc. [AMEX:ORG - news] and Ortec International over
artificial skin for venous ulcers, to the battle between Closure Medical Corp. [Nasdaq:CLSR - news]
and MedLogic Global Corp. over wound closure glues, the report analyzes the relative strengths and
weaknesses of each wound care company.
The report then goes on to rank each company's position in its market according to three parameters:
the strength of its product, the stage of its development and the effectiveness of its distribution
system. The report also offers investment recommendations on four companies on the Wedbush
Morgan wound care research list.
Arrow's report highlights and compares a total of 36 companies (28 public and eight private) in this
industry segment. The public wound care companies included are:
Advanced Tissue Sciences (ATIS), BioSpecifics Corp. (BSTC), Carrington Laboratories (CARN),
Chiron Corp. (Nasdaq:CHIR - news), Closure Medical Corp. (CLSR), Cryolife (CRY), Curative
Health Services (CURE), Cypros Pharmaceuticals (CYP) and Datascope Corp. (Nasdaq:DSCP -
news).
|
